Skip to main content
Top
Published in: Medical Oncology 4/2013

01-12-2013 | Short Communication

Association of polymorphisms in FLT3, EGFR, ALOX5, and NEIL3 with glioblastoma in the Han Chinese population

Authors: Tian-Bo Jin, Xiao-Lan Li, Hua Yang, Mutu Jiri, Xu-Gang Shi, Dong-Ya Yuan, Long-Li Kang, Shan-Qu Li

Published in: Medical Oncology | Issue 4/2013

Login to get access

Abstract

Glioblastoma (GBM) is the highest-grade glioma in astrocytoma. Patients often have poor prognosis due to therapeutic resistance and tumor recurrence. Identification of the genetic factors of GBM could be important contribution to early prevention of this disease. We genotyped 17 tag single-nucleotide polymorphisms (tSNPs) from nine genes in this study, including 72 cases and 302 controls. SNP genotyping was conducted using Sequenom MassARRAY RS1000. Statistical analysis of the association between tSNPs and GBM was performed using the χ 2 test and SNPStats software. The rs3829382 in FLT3 was associated with increased odds of developing GBM using the χ 2 test. When we analyzed tSNPs under different inheritance models, we found rs9642393 in EGFR increased odds of developing GBM in the dominant model. After stratification by gender, we found that rs12645561 in NEIL3 and rs2291427 in ALOX5 were associated with developing GBM. Polymorphisms within FLT3, EGFR, NEIL3, and ALOX5 may contribute to the occurrence of GBM in the Han Chinese population. However, the functional significance of these polymorphisms needs further investigation.
Literature
1.
go back to reference Lawson HC, Sampath P, Bohan E, Park MC, Hussain N, Olivi A, et al. Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol. 2007;83:61–70.CrossRefPubMedCentralPubMed Lawson HC, Sampath P, Bohan E, Park MC, Hussain N, Olivi A, et al. Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol. 2007;83:61–70.CrossRefPubMedCentralPubMed
2.
go back to reference Rossetto M, Hallani SE, Sanson M. The Pro/Pro genotype at TP53 codon 72 polymorphism is associated with early onset glioblastoma. Cancer Genet. 2012;205:677.CrossRefPubMed Rossetto M, Hallani SE, Sanson M. The Pro/Pro genotype at TP53 codon 72 polymorphism is associated with early onset glioblastoma. Cancer Genet. 2012;205:677.CrossRefPubMed
3.
go back to reference Custodio AC, Almeida LO, Pinto GR, Santos MJ, Almeida JR, Clara CA, et al. GSTP1 Ile105Val polymorphism in astrocytomas and glioblastomas. Genet Mol Res. 2010;9:2328–34.CrossRefPubMed Custodio AC, Almeida LO, Pinto GR, Santos MJ, Almeida JR, Clara CA, et al. GSTP1 Ile105Val polymorphism in astrocytomas and glioblastomas. Genet Mol Res. 2010;9:2328–34.CrossRefPubMed
4.
go back to reference Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009;Chapter 2:Unit 2.12. doi:10.1002/0471142905. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009;Chapter 2:Unit 2.12. doi:10.​1002/​0471142905.
5.
go back to reference Thomas RK, Baker AC, DeBiasi RM, Winckler W, LaFramboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–51.CrossRefPubMed Thomas RK, Baker AC, DeBiasi RM, Winckler W, LaFramboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–51.CrossRefPubMed
6.
go back to reference Adamec C. Example of the use of the nonparametric test: test χ 2 for comparison of 2 independent examples. Cesk Zdrav. 1964;12:613–9.PubMed Adamec C. Example of the use of the nonparametric test: test χ 2 for comparison of 2 independent examples. Cesk Zdrav. 1964;12:613–9.PubMed
7.
go back to reference Bland JM, Altman DG. Statistics notes. The odds ratio. Br Med J. 2000;320:1468.CrossRef Bland JM, Altman DG. Statistics notes. The odds ratio. Br Med J. 2000;320:1468.CrossRef
8.
go back to reference Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928–9.CrossRefPubMed Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928–9.CrossRefPubMed
9.
go back to reference Patyna S, Laird AD, Mendel DB, O’farrell AM, Liang C, Guan H, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther. 2006;5:1774–82.CrossRefPubMed Patyna S, Laird AD, Mendel DB, O’farrell AM, Liang C, Guan H, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther. 2006;5:1774–82.CrossRefPubMed
10.
go back to reference Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O’Brien S, Koller C, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34:752–6.CrossRefPubMedCentralPubMed Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O’Brien S, Koller C, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34:752–6.CrossRefPubMedCentralPubMed
11.
go back to reference Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103:3544–6.CrossRefPubMed Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103:3544–6.CrossRefPubMed
12.
go back to reference Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10:4227s–32s.CrossRefPubMed Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10:4227s–32s.CrossRefPubMed
13.
go back to reference Hou WG, Ai WB, Bai XG, Dong HL, Li Z, Zhang YQ, et al. Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population. PLoS One. 2012;7(5):e37531.CrossRefPubMedCentralPubMed Hou WG, Ai WB, Bai XG, Dong HL, Li Z, Zhang YQ, et al. Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population. PLoS One. 2012;7(5):e37531.CrossRefPubMedCentralPubMed
14.
go back to reference Perez CA, Chen H, Shyr Y, Courtney R, Zheng W, Cai Q, et al. The EGFR polymorphism rs884419 is associated with freedom recurrence in patients with resected prostate cancer. J Urol. 2010;183:2062–9.CrossRefPubMedCentralPubMed Perez CA, Chen H, Shyr Y, Courtney R, Zheng W, Cai Q, et al. The EGFR polymorphism rs884419 is associated with freedom recurrence in patients with resected prostate cancer. J Urol. 2010;183:2062–9.CrossRefPubMedCentralPubMed
15.
16.
go back to reference Ishii K, Zaitsu M, Yonemitsu N, Kan Y, Hamasaki Y, Matsuo M. 5-Lipoxygenase pathway promotes cell proliferation in human glioma cell lines. Clin Neuropathol. 2009;28:445–52.CrossRefPubMed Ishii K, Zaitsu M, Yonemitsu N, Kan Y, Hamasaki Y, Matsuo M. 5-Lipoxygenase pathway promotes cell proliferation in human glioma cell lines. Clin Neuropathol. 2009;28:445–52.CrossRefPubMed
Metadata
Title
Association of polymorphisms in FLT3, EGFR, ALOX5, and NEIL3 with glioblastoma in the Han Chinese population
Authors
Tian-Bo Jin
Xiao-Lan Li
Hua Yang
Mutu Jiri
Xu-Gang Shi
Dong-Ya Yuan
Long-Li Kang
Shan-Qu Li
Publication date
01-12-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0718-1

Other articles of this Issue 4/2013

Medical Oncology 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine